Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India [Phase 3]

View source ↗

Summary

Phase 3 trial in adults aged 50 years and older in India evaluating the immune response and safety of a herpes zoster vaccine; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2024-04-08